← Back to Screener
Hyperion DeFi, Inc. Common Stock (HYPD)
Price$4.28
Favorite Metrics
Price vs S&P 500 (26W)-51.88%
Price vs S&P 500 (4W)17.37%
Market Capitalization$48.76M
All Metrics
Book Value / Share (Quarterly)$9.88
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-84.00%
Cash Flow / Share (Quarterly)$-11.51
Price vs S&P 500 (YTD)16.29%
Gross Margin (TTM)-798.11%
Net Profit Margin (TTM)-4868.74%
EPS (TTM)$-17.80
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$-17.80
EPS (Annual)$-59.81
ROI (Annual)-117.07%
Gross Margin (Annual)-6749.02%
Cash / Share (Quarterly)$1.15
Revenue Growth QoQ (YoY)18458.90%
ROA (Last FY)-1358.28%
Revenue Growth TTM (YoY)984.55%
EBITD / Share (TTM)$-2.07
ROE (5Y Avg)-167.48%
Operating Margin (TTM)-4551.99%
Cash Flow / Share (Annual)$-20.10
P/B Ratio0.69x
P/B Ratio (Quarterly)0.97x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-49.34x
ROA (TTM)-54.56%
EPS Incl Extra (Annual)$-59.81
Current Ratio (Annual)0.17x
Quick Ratio (Quarterly)2.14x
3-Month Avg Trading Volume0.36M
52-Week Price Return296.30%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)850.30x
Asset Turnover (Annual)0.02x
52-Week High$17.18
EPS Excl Extra (Annual)$-59.81
CapEx CAGR (5Y)-1.02%
26-Week Price Return-44.99%
Quick Ratio (Annual)0.15x
13-Week Price Return27.76%
Total Debt / Equity (Annual)1.59x
Current Ratio (Quarterly)2.25x
Enterprise Value$48.189
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-86882.51%
Cash / Share (Annual)$1.41
3-Month Return Std Dev118.65%
Net Income / Employee (TTM)$-1
ROE (Last FY)-302.93%
Net Interest Coverage (Annual)-18.46x
EPS Basic Excl Extra (Annual)$-59.81
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-17.80
ROI (TTM)8.45%
P/S Ratio (TTM)141.19x
Revenue / Share (Annual)$0.07
Forward P/E2.92x
Price vs S&P 500 (52W)261.66%
Year-to-Date Return20.22%
5-Day Price Return20.22%
EPS Normalized (Annual)$-59.81
ROA (5Y Avg)-328.38%
Net Profit Margin (Annual)-86882.51%
Month-to-Date Return24.06%
EBITD / Share (Annual)$-57.26
Operating Margin (Annual)-84998.64%
LT Debt / Equity (Annual)1.00x
ROI (5Y Avg)-115.38%
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-17.80
Inventory Turnover (TTM)0.42x
Pretax Margin (TTM)-4868.74%
Price vs S&P 500 (13W)25.38%
Beta2.56x
Revenue / Share (TTM)$0.01
ROE (TTM)9.36%
52-Week Low$1.02
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HYPDHyperion DeFi, Inc. Common Stock | 141.19x | 984.55% | -798.11% | — | $4.28 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Eyenovia is a clinical-stage ophthalmic company developing novel treatments using its proprietary microarray print (MAP) platform and Optejet delivery system—a precision-targeted alternative to conventional eye droppers. The company's pipeline aims to improve drug safety, tolerability, patient compliance, and therapeutic efficacy across multiple eye disease indications. Eyenovia's smart ophthalmic therapies leverage novel formulations and drug combinations powered by its targeted delivery technology.